Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Police Search Drug Regulator's Premises Over Phase I FAAH Study

Executive Summary

French regulator ANSM is under scrutiny following a visit by police investigating the tragic Phase I FAAH inhibitor study, and confirms that it carried out an "internal investigation" whose results have been passed to police and the social affairs inspectorate.

You may also be interested in...



Biotrial Says Will Continue To Cooperate As French Probe Manslaughter Angle in Phase I Case

French prosecutors are beginning judicial proceedings into possible manslaughter following the Phase I trial tragedy in January this year, although CRO Biotrial says the move is "a normal decision" in a complex investigation.

French Trial Tragedy: Experts Recommend Tighter Phase I Rules

The French committee investigating the data behind the Phase I study of Bial's FAAH inhibitor BIA 10-2474, which resulted in the death of one volunteer and the hospitalization of five others in January 2016, has made a number of recommendations for tightening up the regulations on first-in-human studies.

UK Explains New Rules On Parallel Imports From EU

Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel